Generic Prescription Drugs - Your Health. Our Commitment. #Take with Confidence

The Importance of Quality and Competition

Vigorous, ethical competition is the foundation of the generic drug and biosimilar industry. AAM members develop and manufacture medicines that conform to high standards of quality, safety and efficacy as determined by regulatory authorities where they operate.

Read Statement
AAM's 2019 Access & Savings in the U.S. Report

The quality and affordability of generic medicines makes possible greater access, adherence and improved health for millions of patients across the United States.

Read Report
Generic Drugs: Take with Confidence

According to the FDA, “Generic medications are just as safe and effective as their brand-name counterparts, and often cost less.”

Learn More
Be Prepared + Get Approved

Our Justification Toolkit has everything you need to make your case for attending GRx+Biosims 2019.

Open Toolkit
Biosimilars, Biologics and Interchangeability 101

Follow along with this simple, animated white board video to learn about biosimilars, biologics, and how interchangeability can help to increase patient access while decreasing the cost of expensive medicines.

Watch Video
A Call for Session Topics

GRx+Biosims 2019 is seeking conference proposals that reflect the best thinking in the field, informed by research, expertise and experience.

Submit a Topic
Anniversary of the May 10 Trade Amendments

Twelve years ago, lawmakers prioritized patient access to affordable medicine. We can do it again and fix the USMCA!

View Infographic
NAFTA 2.0: Obstacles to More Affordable Medicines

The U.S.-Mexico-Canada Agreement (USMCA) or "NAFTA 2.0" contains obstacles to more affordable meds for Americans. There is still time to #FixUSMCA to put America’s patient first!

View Infographic
Prescription for Savings

Congress can take meaningful action to lower prescription drug costs for patients who rely on affordable medicines to live healthy lives.

Learn More
Access More Opportunity

Powered by AAM, Women in Health Policy (WiHP) is a nonpartisan network that aims to increase the number of women guiding our nation’s health care and to amplify their effectiveness and professional advancement.

Join Now

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Society

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

May 23, 2019 | Rachel Schwartz

AAM Statement on FTC Report on Patent Settlements

May 21, 2019 | Rachel Schwartz

AAM Statement on House Bills 965, 1499 and 938

May 17, 2019 | Rachel Schwartz

AAM Statement on the Importance of Generic and Biosimilar Quality and Robust Competition

May 16, 2019 | Rachel Schwartz

How Generic Drug Makers Are Responding to Price-Fixing Lawsuit

AAM Capitol Hill May 10 Briefing on NAFTA 2.0 with Representative Earl Blumenauer

May 13, 2019 | Erica Klinger

Highlights from the NAFTA 2.0 Congressional Briefing: The May 10 Amendments

May 13, 2019 | Rachel Schwartz

The 11th Annual Edition of AAM Access & Savings Report Finds Generic Savings Totaled $293 Billion in 2018